Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5–7 year follow-up after SCHEDULE heart transplant everolimus de novo study
2016-000404-28Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of everolimus in post-orthotopic heart transplantation status and Cardiac Rejection (2 arms), sponsored by Novartis. Primary endpoint: Renal function (measured GFR). Started Jun 2016; status: completed.
02
Drugs
everolimus
03
Conditions
post-orthotopic heart transplantation statusCardiac Rejection
Beyond the preview
Go deeper on 2016-000404-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000404-28.